IP Library › Granted Patent US 7,125,964
Granted Patent B2
US 7,125,964 · App. 10/785,472 · Granted Oct 24, 2006

Purification of antigen-specific T cells

Assignee: Ortho-McNeil Pharmaceutical, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,125,964
App. No.
10/785,472
Granted
Oct 24, 2006
Kind
B2
Abstract

A new method to capture, purify and expand antigen-specific T lymphocytes has been developed using magnetic beads coated with recombinant MHC class I molecules. This method was optimized using homogenous populations of naive T cells purified from mice transgenic for the 2C T cell receptor (TCR). These T cells were captured on beads coated with MHC class I molecules and the relevant antigenic peptides. MHC and peptide specificity was confirmed by the usage of irrelevant MHC peptide combinations. An enrichment of 800 to 1600 fold was measured, using 2C T cells mixed with irrelevant T cells, starting from a 2C T cell frequency of 1/3000. The same approach was used to purify antigen-specific CD8 + T cells from total CD8 + T cells from naive mice. The recovered cells could be expanded and specifically kill target cells in vitro; they had a significant effect in vivo as well. We expect this procedure to be suitable to purify and expand in vitro tumor- and virus-specific killer T cells for use in cell therapy.

Claims (3)

1. A substrate for capturing antigens, comprising a support having on its surface a population of purified immobilized empty MHC Class I molecules, wherein said MHC Class I molecules are K bm3 or L D molecules expressed from a recombinant Drosophila cell and are capable of binding one or more antigens, and wherein said substrate is not a lipid bilayer.

2. The substrate of claim 1 wherein the substrate is a bead.

3. The substrate of claim 1 wherein the one or more antigens are peptides.

Continuity (4)
Continuation 0943496500 · Nov 5, 1999
Division 0890954900 · Aug 12, 1997
Provisional Application 6002558800 · Sep 6, 1996
Related Publication 20040137617A1 · Jul 15, 2004